Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

By sjmartinez • May 10, 2025

Jhaveri K, Anders CK, Bardia A, Bhave M, Chien AJ, Krop I, Traina TA, Abdou Y, Basho R, Conlin AK, Esteva FJ, Fox KR, Gadi V, Kaufman PA, Litvak A, Ma CX, Mamounas EP, McArthur H, McCann K, Mitri Z, Shatsky R, Telli M, Torres MA, Kalinsky K. Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium. Clin Breast Cancer. 2025 Apr 8:S1526-8209(25)00098-9. doi: 10.1016/j.clbc.2025.04.007. Epub ahead of print. PMID: 40340127.

Tags: AKTi, Antibody-drug conjugates, Breast cancer diagnosis, Breast cancer treatment, CDK4/6i, Hematology/Oncology, Publications, unmet needs

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]